In an ever-changing environment, we are committed in our efforts to ensuring Foundation Medicine is a diverse and inclusive place for all. Our third annual Diversity, Equity and Inclusion (DE&I) report reflects upon the progress we have made in the last year, our reflections on this progress, and our continued efforts to do more within our community and beyond: https://bit.ly/4cHCkJP #WeAreFMI
Foundation Medicine
Biotechnology Research
Boston, Massachusetts 79,060 followers
Find Answers. Take Action. #WeAreFMI
About us
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit us at www.FoundationMedicine.com or follow @FoundationATCG on Twitter. Community Guidelines: bit.ly/FMICommunityGuidelines
- Website
-
http://www.foundationmedicine.com
External link for Foundation Medicine
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2010
- Specialties
- molecular information, cancer genomics, next-generation sequencing, precision medicine, comprehensive genomic profiling, and oncology
Locations
-
Primary
400 Summer St
Boston, Massachusetts 02210, US
-
7010 Kit Creek Road
Morrisville, NC 27560, US
Employees at Foundation Medicine
Updates
-
Results from a new study showcase the value of circulating tumor DNA (ctDNA) monitoring as an additional approach to evaluating clinical response to certain treatments for patients with metastatic castration resistant #prostatecancer. Data indicates that ctDNA tumor fraction can complement prostate-specific antigen (PSA) testing and conventional radiographic assessments while also serving as a strong prognostic factor across treatment time points. Read more in our latest #research spotlight: https://bit.ly/4cXlczG
-
We’re honored to celebrate the LGBTQIA+ community in June and beyond. Last month, colleagues, their families and friends, came together to commemorate #Pride month through various activities and events. Read through the highlights here: https://bit.ly/45X4pKI
-
Approval Announcement – proud to share that our blood-based, liquid biopsy test has been approved by the FDA as a companion diagnostic to help identify patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer who may be appropriate for a specific targeted therapy. This decision follows the approval of our tissue-based test for the same therapy in August 2023. Learn more: https://bit.ly/45OTClB
-
Meet Bianca, an Accessioning Supervisor who has excelled at Foundation Medicine, driven by her genuine love of helping others. A certified nursing assistant for 12 years, Bianca had plans of becoming a nurse until a life event prompted her to pivot into the lab — eventually landing at Foundation Medicine. She has made an immeasurable impact on coworkers and patients by leading with heart. Read our latest #careers #blog to learn about Bianca shares and the dedicated approach that has led to her personal growth and professional success: https://bit.ly/4czjiVC #WeAreFMI
-
Proud to support Living Beyond Breast Cancer on the launch of this campaign and to help increase education and understanding around #biomarker testing. Learn more in the post below.
We're thrilled to announce that the #NoOneMissed campaign has officially launched! In this joint collaboration with LUNGevity Foundation, one of our goals is to increase understanding of biomarker testing and how it can play a key role in helping #healthcareproviders create personalized treatment options for patients. Learn more about this crucial initiative: https://bit.ly/3L1K2T3
-
Today we recognize Juneteenth. While strides have been made, there is still a lot of work to be done in the fight against racial and systemic injustices faced by Black Americans. Within our workplace, our communities and beyond, we can all contribute to fostering places of inclusivity, standing up for justice and speaking out against racism.
-
New #research aimed to inform optimal clinical considerations for comprehensive genomic profiling (CGP) using tissue- & blood-based biopsies in patients with HR-positive, HER2-negative metastatic breast cancer (MBC). Findings showed that CGP can help oncologists better understand why HR-positive, HER2-negative MBC patients show resistance to certain therapies and how to optimize first and subsequent lines of therapy due to acquired resistance mechanisms. Read more here: https://bit.ly/4bfAui4
-
Recognizing National Black Family Cancer Awareness Week. We remain dedicated to spreading knowledge and awareness around cancer within one of the most vulnerable segments of the US population. Through our connections and work in our communities, we are committed to helping enable greater access to precision medicine and to making cancer care more equitable. Click through below for some key facts and information. #BlackFamCan